Enzastaurin
![]() | |
Names | |
---|---|
Preferred IUPAC name
3-(1-Methyl-1H-indol-3-yl)-4-(1-{1-[(pyridin-2-yl)methyl]piperidin-4-yl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione | |
Other names
LY-317615
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.233.143 ![]() |
IUPHAR/BPS
|
|
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C32H29N5O2 | |
Molar mass | 515.617 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
![]() ![]() ![]() | |
Infobox references | |
Enzastaurin is a synthetic bisindolylmaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply, preventing growth.
In 2013 it failed a phase III clinical trial for lymphoma.[1]
References[]
External links[]
- Enzastaurin hydrochloride, National Institutes of Health
Categories:
- Pyridines
- Piperidines
- Bisindolylmaleimides
- Orphan drugs